Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.69 |
| ▸ | CTSS | P25774 | 3/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.69 |
| ▸ | CTSH | P09668 | 1/20 | 0.67 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.59 |
| ▸ | GLP1R | P43220 | 4/20 | 0.55 |
| ▸ | GCGR | P47871 | 4/20 | 0.55 |
| ▸ | GIPR | P48546 | 1/20 | 0.55 |
| ▸ | NMBR | P28336 | 2/20 | 0.55 |
| ▸ | GRPR | P30550 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677323 | 0.94 | CTSL (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29387696 | 0.94 | CTSL (0.64) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29513768 | 0.92 | CTSL (0.62) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL32659744 | 0.89 | C5AR1 (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30600019 | 0.89 | C5AR1 (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29793911 | 0.89 | C5AR1 (0.64) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30574265 | 0.88 | C5AR1 (0.56) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29390561 | 0.87 | C5AR1 (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL31757090 | 0.87 | C5AR1 (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL31150419 | 0.87 | CTSL (0.63) | CTSLCTSSCTSKCTSHC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587450-A1 | MODIFIED CHOLIC ACID CONJUGATES | Ultra, LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120202209-A | Modified cholic acid conjugate | 乌尔特拉有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20240335547-A1 | MODIFIED CHOLIC ACID CONJUGATES | ULTRA, LLC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024058975-A1 | MODIFIED CHOLIC ACID CONJUGATES | ULTRA, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335547-A1 | MODIFIED CHOLIC ACID CONJUGATES | MMAB, NR1H4, CHKB | CTSL 2927/4885CTSS 2407/4885CTSK 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.